Literature DB >> 10332431

Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus.

A D Kohan1, N A Armenakas, J A Fracchia.   

Abstract

PURPOSE: We evaluate the clinical, diagnostic and radiographic findings in patients on indinavir therapy who presented with renal colic, and propose appropriate treatment options for indinavir urolithiasis.
MATERIALS AND METHODS: A total of 16 patients positive for human immunodeficiency virus on indinavir were evaluated for 18 episodes of severe renal colic requiring hospitalization. Laboratory evaluation was performed in all patients followed by an imaging study. Conservative treatment included intravenous hydration, narcotic analgesics and temporary cessation of indinavir. Intervention was elected only in patients with persistent fever or intractable pain. A month after hospital discharge an excretory urogram and metabolic stone evaluation were performed. Mean followup was 9.3 months and 2 patients had recurrent symptoms.
RESULTS: All patients presented with nausea or vomiting and hematuria. Imaging studies confirmed obstruction in all patients with 13 radiolucent (indinavir) and 3 radiopaque (calcium oxalate) stones. Patients with radiolucent and radiopaque stones demonstrated significant differences in urinary pH (p = 0.002) and serum creatinine (p = 0.03). Conservative therapy was successful in 11 patients (68.8%) within 48 hours and 4 patients (25%) with radiolucent calculi required endoscopic stenting for persistent fever. Metabolic stone evaluation demonstrated significant hypocitruria (less than 50 mg./24 hours) in all patients with radiolucent calculi.
CONCLUSIONS: The urologist should be familiar with this growing cause of renal colic in patients on indinavir therapy. Pure indinavir stones are radiolucent and have a soft, gelatinous endoscopic appearance. Conservative treatment is successful in most patients and if intervention is deemed medically necessary, endoscopic stent placement should be the procedure of choice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10332431     DOI: 10.1016/s0022-5347(05)68795-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

Review 1.  HIV-associated immune complex kidney disease.

Authors:  Ehsan Nobakht; Scott D Cohen; Avi Z Rosenberg; Paul L Kimmel
Journal:  Nat Rev Nephrol       Date:  2016-01-19       Impact factor: 28.314

Review 2.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

3.  Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension.

Authors:  Trinity Vera; David E Stec
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-07-28       Impact factor: 3.619

4.  Renal Dysfunction in HIV-1-infected Patients.

Authors:  Jeffrey B. Kopp
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

5.  Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice.

Authors:  Trinity Vera; Joey P Granger; David E Stec
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-01       Impact factor: 3.619

Review 6.  Urologic complications of HIV and AIDS.

Authors:  Chris F Heyns; Adam E Groeneveld; Nelson B Sigarroa
Journal:  Nat Clin Pract Urol       Date:  2009-01

Review 7.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Retrograde ejaculation associated spontaneous sperm cystolithiasis in four rhesus macaques (Macaca mulatta).

Authors:  Sanjeev Gumber; Cynthia L Courtney; Karen R Strait; Prachi Sharma; Julie E Freebersyser; Maria M Crane
Journal:  Exp Toxicol Pathol       Date:  2013-06-02

9.  Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy.

Authors:  Julie Huynh; Aviv Hever; Thomas Tom; John J Sim
Journal:  Int Urol Nephrol       Date:  2010-05-11       Impact factor: 2.370

Review 10.  Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV.

Authors:  Milena M McLaughlin; Aimee J Guerrero; Andrew Merker
Journal:  Drugs Context       Date:  2018-03-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.